Evidence map›Paper›PMID 37473549›Full record

ArticleBiosensors & bioelectronics2023

Miniaturized microarray-format digital ELISA enabled by lithographic protein patterning.

Andrew D Stephens, Yujing Song, Brandon L McClellan, Shiuan-Haur Su, Sonnet Xu, Kevin Chen, Maria G Castro, Benjamin H Singer, Katsuo Kurabayashi

Open access · greenAbstract read
In one paragraph

Article in Biosensors & bioelectronics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
3.5field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 23 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Andrew D StephensDepartment of Mechanical Engineering, University of Michigan, Ann Arbor, MI, 48109, USA.
Yujing SongDepartment of Mechanical Engineering, University of Michigan, Ann Arbor, MI, 48109, USA.
Brandon L McClellanDepartment of Neurosurgery, University of Michigan Medical School, Ann Arbor, MI, 48109, USA; Department of Cell and Developmental Biology, University of Michigan Medical School, Ann Arbor, MI, 48109, USA; Graduate Program in Immunology, University of Michigan Medical School, Ann Arbor, MI, 48109, USA.
Shiuan-Haur SuDepartment of Mechanical Engineering, University of Michigan, Ann Arbor, MI, 48109, USA.
Sonnet XuDepartment of Mechanical Engineering, University of Michigan, Ann Arbor, MI, 48109, USA.
Kevin ChenDepartment of Biomedical Engineering, University of Michigan, Ann Arbor, MI, 48109, USA.
Maria G CastroDepartment of Neurosurgery, University of Michigan Medical School, Ann Arbor, MI, 48109, USA; Department of Cell and Developmental Biology, University of Michigan Medical School, Ann Arbor, MI, 48109, USA; Rogel Cancer Center, University of Michigan, Ann Arbor, MI, 48109, USA.
Benjamin H SingerDepartment of Internal Medicine, Division of Pulmonary and Critical Care Medicine, University of Michigan, Ann Arbor, MI, 48109, USA; Weil Institute for Critical Care Research and Innovation, University of Michigan, Ann Arbor, MI, 48109, USA.
Katsuo KurabayashiDepartment of Mechanical and Aerospace Engineering, New York University, Brooklyn, NY, 11201, USA. Electronic address: kk5165@nyu.edu.
University of Michigan · USNew York University · US

Funding

XenograftP30CA046592 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Alexey I Nesvizhskii · 1988 to 2026
$178.2M
RESEARCH TRAINING IN EXPERIMENTAL IMMUNOPATHOLOGYT32AI007413 · NIAID · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Bethany B. Moore · 1993 to 2026
$9.8M
Enhancement of Brain Dysfunction in Sepsis Survivors by Alzheimer’s Disease NeuropathologyR01AG074968 · NIA · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Benjamin Herschel Singer · 2022 to 2026
$3.3M
Systemic Delivery of Targeted Bi-Compartmental Nanoparticles for Glioblastoma Therapeutics (Supplement)R01NS124167 · NINDS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Maria G Castro, JOERG LAHANN · 2022 to 2026
$2.6M
Novel nano-vaccine technology for inducing immunity against gliomasR01NS122536 · NINDS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI CASTRO, MARIA G, MOON, JAMES J. · 2021 to 2025
$2.6M
Uncover the role of H3.3-G343R mutation in shaping the DNA damage response, anti-tumor immunity and mechanisms of resistance in glioma.R01NS122165 · NINDS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Maria G Castro · 2022 to 2026
$2.5M
The µSiM-hNVU - a human BBB platform for the study of brain injury mechanisms during systemic infectionR33HL154249 · NHLBI · UNIVERSITY OF ROCHESTER · PI ENGELHARDT, BRITTA, GABORSKI, THOMAS R · 2022 to 2024
$2.2M
The µSiM-hNVU - a human BBB platform for the study of brain injury mechanisms during systemic infectionR61HL154249 · NHLBI · UNIVERSITY OF ROCHESTER · PI ENGELHARDT, BRITTA, GABORSKI, THOMAS R · 2020 to 2021
$1.2M
Chemo-immunotherapy strategy for pediatric high grade gliomaR21NS123879 · NINDS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI CASTRO, MARIA G, SCHWENDEMAN, ANNA · 2021 to 2021
$429k
NCI NIH HHS P30 CA046592NHLBI NIH HHS R33 HL154249NHLBI NIH HHS R61 HL154249NIAID NIH HHS T32 AI007413NIA NIH HHS R01 AG074968NINDS NIH HHS R01 NS122165NINDS NIH HHS R01 NS122536NINDS NIH HHS R01 NS124167NINDS NIH HHS R21 NS123879
6 · The paper itself

Abstract

The search for reliable protein biomarker candidates is critical for early disease detection and treatment. However, current immunoassay technologies are failing to meet increasing demands for sensitivity and multiplexing. Here, the authors have created a highly sensitive protein microarray using the principle of single-molecule counting for signal amplification, capable of simultaneously detecting a panel of cancer biomarkers at sub-pg/mL levels. To enable this amplification strategy, the authors introduce a novel method of protein patterning using photolithography to subdivide addressable arrays of capture antibody spots into hundreds of thousands of individual microwells. This allows for the total sensor area to be miniaturized, increasing the total possible multiplex capacity. With the immunoassay realized on a standard 75x25 mm form factor glass substrate, sample volume consumption is minimized to <10 μL, making the technology highly efficient and cost-effective. Additionally, the authors demonstrate the power of their technology by measuring six secretory factors related to glioma tumor progression in a cohort of mice. This highly sensitive, sample-sparing multiplex immunoassay paves the way for researchers to track changes in protein profiles over time, leading to earlier disease detection and discovery of more effective treatment using animal models.

Indexed as

Biosensing TechniquesAnimalsBiomarkers, TumorEnzyme-Linked Immunosorbent AssayImmunoassayMiceProteinsBiomarkers, TumorProteinsBiomarker discoveryDigital immunoassayGlioma mouse modelMultiplex biomarker detectionProtein microarrayProtein patterning

Identifiers

PMID37473549
PMCPMC10528924
OpenAlexW4384469885

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.